Skip to main content
Menu
Search
EN
DE
Company
MorphoSys in a Nutshell
Company
Main Menu
Sustainable business model
Main Menu
Balanced business model
Research and development
Management
Main Menu
Management Board
Supervisory Board
Subsidiaries
Main Menu
Lanthio Pharma
MorphoSys US Inc.
History
Main Menu
Contact
Main Menu
Media and investors
Business development
Innovation capital
Careers
Drug safety
Pipeline
The Therapeutic Pipeline
Pipeline
Main Menu
Clinical development expertise
Main Menu
Clinical Development
Drug Safety
Regulatory Affairs
Quality Assurance
Proprietary portfolio
Main Menu
Tafasitamab (MOR208)
MOR202
Otilimab (MOR103/GSK3196165)
MOR106
MOR107
Product on market
Main Menu
Tremfya® (guselkumab)
Science
Engineering the Medicines of Tomorrow
Science
Main Menu
Scientific research expertise
Main Menu
Discovery, Alliances and Technologies
Protein Sciences
Preclinical Development
Our Technologies
Main research areas
Main Menu
Cancer
Immuno-oncology
Inflammatory and autoimmune Diseases
Antibodies targeting GPCRs
Lanthipeptides
External Scientific Advisory Board (SAB)
Main Menu
Partnering
MorphoSys as a Partner
Partnering
Main Menu
Partnering expertise
Main Menu
Business Development
Alliance Management
Partnering opportunities
Main Menu
Early-stage
Mid-stage
Late-stage
Technology
Contact
Innovation Capital
Main Menu
Innovation capital
Investment approach
Portfolio companies
Contact
Media and investors
Invest in the Medicines of Tomorrow
Media and investors
Main Menu
Stock information
Main Menu
General information
Stock charts
Share price performance
Recent voting rights notifications
Analysts
ADS
Share buy-back
Investor & Media information
Main Menu
Corporate releases
Order form for publications and reports
SEC-Filings
Ad-hoc releases
Presentations and Conferences
Pictures
Awards & Recognition
Financial information
Main Menu
Financial guidance
Fundamentals
Business segments
Financial reports
MorphoSys events
Main Menu
Company calendar
Upcoming conferences
Conference Archive
Corporate governance
Main Menu
Corp.Gov Declaration of Conformity
Managers’ Transactions
Remuneration Report
Annual General Meeting
Main Menu
AGM Archive
Career
Working with us
Career at MorphoSys
Main Menu
Welcome to career at MorphoSys
Main Menu
MorphoSys as employer
Main Menu
Your Career
Main Menu
Your application
Main Menu
Vacancies
Main Menu
Info Request
You are here
Home
Info Request
Printed Reports
3rd Quarter Interim Statement 2019
English
German
Annual Report 2018
English
German
Annual Report 2017
English
German
Annual Report 2013
English
German
E-Mail Services
Press Releases
English
German
Annual Report
English
German
Quarterly Reports
English
German
Subscription to regularly receive printed copies of new reports
Annual Report
English
German
Quarterly Reports
English
German
Personal Information
Salutation
* @
Please select
Mr.
Mrs.
First Name
* @
Last Name
* @
Title
Please select
Dr.
Prof.
PhD.
Position
Company / Organization
Which group describes you best?
Please select
Investor, institutional
Investor, private
Press
Other
Contact Information
Street
*
ZIP
*
City
*
Country
*
Please select
Afghanistan
Albania
Algeria
Andorra
Angola
Antigua
Argentina
Armenia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Fiji
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Grenada
Guadeloupe
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Irak
Iran
Irish Republic
Israel
Italy
Jamaica
Japan
Jordan
Kazakstan
Kenya
Kiribati
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Morocco
Mozambique
Namibia
Nauru
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
North Korea
Norway
Oman
Pakistan
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Romania
Russia
Rwanda
Saint Kitts
Saint Lucia
Saint Vincent
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
Spain
Sri Lanka
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
Uruguay
USA
Uzbekistan
Vanuatu
Venezuela
Vietnam
Yemen
Zaire
Zambia
Zimbabwe
County
*
Please select
Alabama
Alaska
American Samoa
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia (Washington, D.C.)
Federated States of Micronesia
Florida
Georgia
Guam
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Marshall Islands
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Northern Mariana Islands
Ohio
Oklahoma
Oregon
Palau
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Telephone
Fax
Mobile
E-mail
* @
*
Required fields for Subscription /
@
Required fields for E-Mail Services
Comments/Questions
Comment/Questions
With regard to the acquisition, usage and processing of personal data, MorphoSys is in compliance with the relevant provisions of data protection law. MorphoSys acquires, processes and uses the personal data which have been provided by you only for the agreed purposes. MorphoSys does not sell or market your personal data. In case you do not any more wish to receive information from MorphoSys, we kindly ask you to inform us accordingly via e-mail (
investors@morphosys.com
). We will then remove your name from our distribution list.